Clinical trials: Camrelizumab
Breast Cancer Stage IV, Triple -Negative Breast Cancer
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall…
- Trial name
- NCT06889688
- Testing
- Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy
- Where
- 7 sites in China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Hepatocellular Carcinoma (HCC)
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.
- Trial name
- HCC-IM-1 (NCT07147101)
- Testing
- Sintilimab, Bevacizumab Biosimilar, Camrelizumab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC)
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure.
- Trial name
- HCC-SIGHT (NCT07328009)
- Testing
- Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fudan University
Triple-negative Breast Cancer
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
- Trial name
- NCT05749588
- Testing
- A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab with famitinib, B1: TROP2 ADC
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus…
- Trial name
- STELLAR01 (NCT07530094)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Ning Jiang, M.D./Ph.D.
Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide.
- Conditions
- Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
- Trial name
- NCT06485466
- Testing
- TACE plus camrelizumab and apatinib, Camrelizumab and apatinib
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Guohui Xu
Locally Advanced Rectal Cancer
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for…
- Trial name
- NCT07527026
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chinese PLA General Hospital
Rectal Cancer Patients
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer
This study is for adults with locally advanced rectal cancer that has not spread to distant organs, and is classified as pMMR or MSS (which means it typically does not respond well to immunotherapy alone).
- Trial name
- NCT07521605
- Testing
- Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Guangdong Provincial People's Hospital
Squamous Cell Carcinoma of Head and Neck
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of camrelizumab in combination with cetuximab and chemotherapy as first-line for patients with relapsed/metastastic head and neck squamous…
- Trial name
- NCT05673577
- Testing
- Camrelizumab+cetuximab+chemotherapy
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Fudan University
Salivary Gland Carcinoma, Precision Therapy
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and…
- Trial name
- NCT06145308
- Testing
- Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College
Esophageal Squamous Cell Carcinoma
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Palbociclib, as a new neoadjuvant treatment…
- Trial name
- NCT06654297
- Testing
- Camrelizumab, Palbociclib(100mg), Palbociclib(125mg)
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of…
- Trial name
- NCT05656131
- Testing
- Fluzoparib, Fluzoparib+Camrelizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- wang shusen
Gastric Cancer, Second-line Therapy
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2)…
- Trial name
- NCT07320586
- Testing
- Camrelizumab, Nab paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Tumor Hospital
Breast Cancer Triple Negative Breast Cancer
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Treatment of triple-negative breast cancer (TNBC) remains a significant challenge. Although immune checkpoint inhibitors combined with chemotherapy have achieved breakthroughs, drug resistance persists, leaving clinical needs…
- Trial name
- NCT07471815
- Testing
- Camrelizumab + Risedronate Sodium + Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Harbin Medical University
Cervical Cancer, Radical Surgery
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer…
- Conditions
- Cervical Cancer, Radical Surgery, Adjuvant Therapy
- Trial name
- NCT07466901
- Testing
- Camrelizumab, famotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jin LI
Nasopharyngeal Carcinoma
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication…
- Trial name
- NCT06239727
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2)
- Where
- 26 sites in China
- Volunteers
- 593 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
This is a multi-center, open-label, Phase II study of intravenous (IV) SHR-1210 at 200mg, q2w in combination with Apatinib at two dose levels in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT03083041
- Testing
- SHR-1210, Apatinib
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rectal Cancer
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)
The study is a multicenter, open-label, randomized controlled clinical study, and the purpose of the study is to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with…
- Trial name
- NCT04928807
- Testing
- Short course radiotherapy sequential camrelizumab and chemotherapy
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Head and Neck Squamous Cell Carcinoma
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a prospective, randomized, controlled, multicenter, non-inferiority clinical study designed to evaluate the efficacy and safety of camrelizumab combined with EGFR monoclonal antibody or chemotherapy as perioperative…
- Trial name
- NCT07432087
- Testing
- Camrelizumab and Cetuximab, Camrelizumab and Chemotherapy
- Volunteers
- 246 people
- Sponsor
- Yue He, MD
Advanced Biliary Tract Carcinoma
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
This is a phase II open-label, one-arm, multicenter study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) treatment for patients with advanced biliary tract carcinoma.
- Trial name
- NCT05451290
- Testing
- Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University